ACE-031 vs IGF-2

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Insulin-like growth factor 2 (IGF-2) is a naturally occurring peptide growth factor structurally homologous to IGF-1 that plays a central role in embryonic development and remains expressed in adult skeletal muscle, where it functions as an autocrine regulator of myoblast differentiation and myocyte maturation downstream of MyoD activation. IGF-2 binds both the IGF-1 receptor (IGF-1R), which mediates PI3K/Akt anabolic signaling, and the mannose-6-phosphate/IGF-2 receptor (M6P/IGF-2R), which targets bound ligand for lysosomal degradation rather than intracellular signal transduction; the balance between these receptor populations influences net downstream anabolic signaling. Preclinical and cell biology research demonstrates that autocrine IGF-2 signaling through IGF-1R is required for normal myocyte maturation, and that TGF-β-mediated suppression of IGF-2 autocrine pathways impairs skeletal muscle differentiation, establishing IGF-2 as a functionally important endogenous anabolic signal in muscle regeneration. IGF-2 has no FDA-approved applications in performance enhancement or muscle anabolism; exogenous administration as a research compound is investigational and no human clinical trials have established safety or efficacy for these uses.